• Bock, O., Schlue, J., Mengel, M., Busche, G., Serinsoz, E. & Kreipe, H. (2004) Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders. The Journal of Pathology, 203, 609615.
  • Bord, S., Frith, E., Ireland, D.C., Scott, M.A., Craig, J.I. & Compston, J.E. (2004) Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. British Journal of Haematology, 126, 244251.
  • Bord, S., Frith, E., Ireland, D.C., Scott, M.A., Craig, J.I. & Compston, J.E. (2005) Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. Bone, 36, 812819.
  • Bucay, N., Sarosi, I., Dunstan, C.R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H.L., Xu, W., Lacey, D.L., Boyle, W.J. & Simonet, W.S. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes & Development, 12, 12601268.
  • Buhr, T., Büsche, G., Choritz, H., Länger, F. & Kreipe, H. (2003) Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. The American Journal of Clinical Pathology, 119, 152158.
  • Chagraoui, H., Tulliez, M., Smayra, T., Komura, E., Giraudier, S., Yun, T., Lassau, N., Vainchenker, W. & Wendling, F. (2003a) Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood, 101, 29832989.
  • Chagraoui, H., Sabri, S., Capron, C., Villeval, J.L., Vainchenker, W. & Wendling, F. (2003b) Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. Experimental Hematology, 31, 10811088.
  • Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W. & Osdoby, P. (2001) Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. The Journal of Biological Chemistry, 276, 2065920672.
  • Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F. & Heymann, D. (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. The American Journal of Pathology, 163, 20212031.
  • Hofbauer, L.C. & Schoppet, M. (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. Journal of the American Medical Association, 292, 490495.
  • Kanazawa, K. & Kudo, A. (2005) TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. Journal of Bone and Mineral Research, 20, 840847.
  • Kukita, T., Wada, N., Kukita, A., Kakimoto, T., Sandra, F., Toh, K., Nagata, K., Iijima, T., Horiuchi, M., Matsusaki, H., Hieshima, K., Yoshie, O. & Nomiyama, H. (2004) RANKL-induced DC-STAMP is essential for osteoclastogenesis. The Journal of Experimental Medicine, 200, 941946.
  • Lee, N.K., Choi, Y.G., Baik, J.Y., Han, S.Y., Jeong, D.W., Bae, Y.S., Kim, N. & Lee, S.Y. (2005) A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood. 10.1182/blood-2004-09-3662. [Epub ahead of print].
  • Livak, K.J. & Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25, 402408.
  • Malyankar, U.M., Scatena, M., Suchland, K.L., Yun, T.J., Clark, E.A. & Giachelli, C.M. (2000) Osteoprotegerin is an alpha v beta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. The Journal of Biological Chemistry, 275, 2095920962.
  • Mesa, R.A., Steensma, D.P., Pardanani, A., Li, C.Y., Elliott, M., Kaufmann, S.H., Wiseman, G., Gray, L.A., Schroeder, G., Reeder, T., Zeldis, J.B. & Tefferi, A. (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 101, 25342541.
  • Pearse, R.N., Sordillo, E.M., Yaccoby, S., Wong, B.R., Liau, D.F., Colman, N., Michaeli, J., Epstein, J. & Choi, Y. (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 98, 1158111586.
  • Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., Chang, M.S., Luthy, R., Nguyen, H.Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H.L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T.M., Hill, D., Pattison, W., Campbell, P. & Boyle, W.J. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89, 309319.
  • Sordillo, E.M. & Pearse, R.N. (2003) RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer, 97(Suppl. 3), 802812.
  • Tefferi, A. (2000) Myelofibrosis with myeloid metaplasia. New England Journal of Medicine, 342, 12551265.
  • Wang, J.C., Hemavathy, K., Charles, W., Zhang, H., Dua, P.K., Novetsky, A.D., Chang, T., Wong, C. & Jabara, M. (2004) Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). Experimental Hematology, 32, 905910.
  • Ward, H.P. & Block, M.H. (1971) The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore), 50, 357420.
  • von Wasielewski, R., Mengel, M., Gignac, S., Wilkens, L., Werner, M. & Georgii, A. (1997) Tyramine amplification technique in routine immunohistochemistry. The Journal of Histochemistry and Cytochemistry, 45, 14551459.
  • von Wasielewski, R., Mengel, M., Wiese, B., Rudiger, T., Muller-Hermelink, H.K. & Kreipe, H. (2002) Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. The American Journal of Clinical Pathology, 118, 675682.